New Story
Suven Life share price plunges 19% after Alzheimer molecule disappoints in Phase 2
December 1, 2019 | By Moneycontrol.com
business
The triple therapy of Masupirdine (SUVN-502) with Donepezil and Memantine proof of concept phase 2 study missed its pre-specified primary endpoint.
:
Suven Life Sciences share price plunged 19 percent intraday on December 2 after the company announced top-line results of SUVN-502 (Masupirdine) Phase 2A study in patients with Moderate Alzheimer''s Disease (AD). The first of its kind trial which focused on
...
It’s time to compare and apply for the best loan offers at Afinoz. We are a leading online financial marketplace for Personal Loans, Business Loan,Education Loan,Home Loan & Car Loan and Investment Products. Our system intelligence and the automated system offers the best options to you for the real-time tracking of your loan application in an easy manner. Stay tuned to latest updates in the industry at Afinoz.com
blog
Biocon tumbles 3% on 5 USFDA observations for Beng...
January 26, 2020
blog
Facebook blames Apple for Amazon CEO Jeff Bezos’ p...
January 26, 2020
blog
Air India sell off: In second attempt, Centre offe...
January 26, 2020
blog
Amid Jeff Bezos Hack Row, Details Of Spyware In In...
January 26, 2020
blog
Government invites bid for sale of 100% stake in A...
January 26, 2020
blog
Top buy and sell ideas by Ashwani Gujral, Sudarsha...
January 26, 2020
blog
Air India EoI out; govt to completely exit airline
January 26, 2020
blog
In revised push, government announces plans to sel...
January 26, 2020
Check your Personal Loan Eligibility
To check how much loan you can get.
Loan Amount
Monthly Income?
EMI's
Email
Company Name
Mobile Number
Verify

Related News:-